While anti-PD-1 and anti-PD-L1 monoclonal antibodies have revolutionized melanoma therapy [25,26], their use is limited by cost, immune-related side effects, and inconsistent patient responses [21]. This evidence concerns the gene PDCD1 and melanoma.